Clinical Report: FDA clears targeted cholangiocarcinoma therapy
Overview
The FDA has approved lirafugratinib for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements. The approval is based on the REFOCUS trial, which demonstrated a 46% objective response rate and a median response duration of 11.8 months.
Background
Cholangiocarcinoma is a rare and aggressive malignancy with limited treatment options, particularly for patients with unresectable or metastatic disease. Targeted therapies, such as those inhibiting fibroblast growth factor receptors (FGFR), are being explored for this patient population.
Data Highlights
| Measure | Value |
|---|---|
| Objective Response Rate | 46% |
| Median Duration of Response | 11.8 months |
| Recommended Dose | 70 mg once daily |
Key Findings
- Lirafugratinib is approved for adults with unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or rearrangements.
- The REFOCUS trial enrolled 116 patients and reported an objective response rate of 46%.
- The median duration of response for lirafugratinib was 11.8 months.
- Key safety warnings include ocular toxicity, hyperphosphatemia, and embryo-fetal toxicity.
- Lirafugratinib received breakthrough therapy and orphan drug designations from the FDA.
Clinical Implications
Healthcare providers should monitor for potential side effects, particularly ocular toxicity and hyperphosphatemia, during treatment with lirafugratinib.
Conclusion
The approval of lirafugratinib marks a significant advancement in the treatment of cholangiocarcinoma, providing a targeted therapy option for a challenging patient population.
Related Resources & Content
- FDA, FDA, 2026 -- FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma
- The ASCO Post — FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
- the asco post — Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
- ASCO Publications — Personalized Therapy in Advanced Cholangiocarcinoma: Contemporary Treatment Approaches and Future Directions
- ASCO Publications — Efficacy and safety of tislelizumab and apatinib combined with hepatic arterial infusion chemotherapy for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 study.
- FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
- Zenocutuzumab Shows Durable Antitumor Activity in NRG1-Positive Cholangiocarcinoma
- Personalized Therapy in Advanced Cholangiocarcinoma: Contemporary Treatment Approaches and Future Directions
- FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma | FDA
- An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 - PMC
- ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
